[2] [2] Natale A, Mohanty S, Sanders P, et al. Catheter ablation for atrial fibrillation: indications and future perspective[J]. Eur Heart J, 2024, 45(41): 4383-4398.

[3] [3] Kostin S, Richter M, Ganceva N, et al. Atrial fibrillation in human patients is associated with increased collagen type V and TGFbeta1[J]. Int J Cardiol Heart Vasc, 2023, 50: 101327.

[4] [4] Tian Y, Wang Y, Chen W, et al. Role of serum TGF-beta1 level in atrial fibrosis and outcome after catheter ablation for paroxysmal atrial fibrillation[J]. Medicine (Baltimore), 2017, 96(51): e9210.

[6] [6] Xiao JW, Zhang Y, Tang Y, et al. MiRNA-1202 promotes the TGF-1-induced proliferation, differentiation and collagen production of cardiac fibroblasts by targeting nNOS[J]. PLoS One, 2021, 16(8): e0256066.

[7] [7] Wang HC, Chen YQ, Zhao ST, et al. Effect of Sox9 on TGF-1-mediated atrial fibrosis[J]. Acta Biochim Biophys Sin (Shanghai), 2021, 53(11): 1450-1458.

[8] [8] Liu Y, Yin Z, Xu X, et al. Crosstalk between the activated Slit2-Robo1 pathway and TGF-1 signalling promotes cardiac fibrosis[J]. ESC Heart Fail, 2021, 8(1): 447-460.

[9] [9] Isola G, Polizzi A, Alibrandi A, et al. Analysis of galectin-3 levels as a source of coronary heart disease risk during periodontitis[J]. J Periodontal Res, 2021, 56(3): 597-605.

[10] [10] Clementy N, Piver E, Bisson A, et al. Galectin-3 in atrial fibrillation: mechanisms and therapeutic implications[J]. Int J Mol Sci, 2018, 19(4): 976.

[11] [11] Ruan ZB, Gao RF, Wang F, et al. Circulating galectin-3 and aldosterone for predicting atrial fibrillation recurrence after radiofrequency catheter ablation[J]. Cardiovasc Ther, 2022, 2022: 6993904.

[12] [12] Pranata R, Yonas E, Chintya V, et al. Serum galectin-3 level and recurrence of atrial fibrillation post-ablation- systematic review and meta-analysis[J]. Indian Pacing Electrophysiol J, 2020, 20(2): 64-69.

[15] [15] Begg GA, Karim R, Oesterlein T, et al. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study[J]. PLoS One, 2018, 13(1): e0189936.

[16] [16] Morita H, Hoshiga M. Fibroblast growth factors in cardiovascular disease[J]. J Atheroscler Thromb, 2024, 31(11): 1496-1511.

[17] [17] Mizia-Stec K, Wieczorek J, Polak M, et al. Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation[J]. Cytokine, 2018, 111: 106-111.

[19] [19] Dong QB, Li SC, Wang WX, et al. FGF-23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways[J]. J Cell Physiol, 2019, 234(11): 19502-19510.

[20] [20] Tan R, Yu H, Han X, et al. Circulating soluble suppression of tumorigenicity 2 predicts recurrence after radiofrequency ablation of persistent atrial fibrillation[J]. Front Cardiovasc Med, 2021, 8: 653312.

[21] [21] Fan J, Li Y, Yan Q, et al. Higher serum sST2 is associated with increased left atrial low-voltage areas and atrial fibrillation recurrence in patients undergoing radiofrequency ablation[J]. J Interv Card Electrophysiol, 2022, 64(3): 733-742.

[23] [23] Badoz M, Serzian G, Favoulet B, et al. Impact of midregional N-terminal pro-atrial natriuretic peptide and soluble suppression of tumorigenicity 2 levels on heart rhythm in patients treated with catheter ablation for atrial fibrillation: the biorhythm study[J]. J Am Heart Assoc, 2021, 10(13): e20917.

[24] [24] Carballo D, Noble S, Carballo S, et al. Biomarkers and arrhythmia recurrence following radiofrequency ablation of atrial fibrillation[J]. J Int Med Res, 2018, 46(12): 5183-5194.

[25] [25] Li XT, Peng S, Wu XY, et al. C-reactive protein and atrial fibrillation: insights from epidemiological and Mendelian randomization studies[J]. Nutr Metab Cardiovasc Dis, 2022, 32(6): 1519-1527.

[26] [26] Wu N, Xu B, Xiang Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis[J]. Int J Cardiol, 2013, 169(1): 62-72.

[27] [27] Psychari SN, Chatzopoulos D, Iliodromitis EK, et al. C-reactive protein, interleukin 6, and N-terminal pro-brain natriuretic peptide following cardioversion of atrial fibrillation: is there a role of biomarkers in arrhythmia recurrence?[J]. Angiology, 2011, 62(4): 310-316.

[28] [28] Lewicka E, Dudzinska-Gehrmann J, Dabrowska-Kugacka A, et al. Neopterin and interleukin-6 as predictors of recurrent atrial fibrillation[J]. Anatol J Cardiol, 2016, 16(8): 563-571.

[29] [29] Liu YH, Luo D, Liu EZ, et al. MiRNA21 and IL-18 levels in left atrial blood in patients with atrial fibrillation undergoing cryoablation and their predictive value for recurrence of atrial fibrillation[J]. J Interv Card Electrophysiol, 2022, 64(1): 111-120.

[30] [30] AlKassas A, Fouda M, Fassini G, et al. Pre-procedural high serum visfatin and tumor necrosis factor-alpha might predict recurrent atrial fibrillation after catheter ablation[J]. Egypt Heart J, 2023, 75(1): 63.

[31] [31] Bazoukis G, Letsas KP, Vlachos K, et al. Simple hematological predictors of AF recurrence in patients undergoing atrial fibrillation ablation[J]. J Geriatr Cardiol, 2019, 16(9): 671-675.

[32] [32] Yano M, Egami Y, Ukita K, et al. Atrial fibrillation type modulates the clinical predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation recurrence after catheter ablation[J]. Int J Cardiol Heart Vasc, 2020, 31: 100664.

[33] [33] Huang WC, Sun HX, Tang Y, et al. Platelet-to-lymphocyte ratio improves the predictive ability of the risk score for atrial fibrillation recurrence after radiofrequency ablation[J]. J Inflamm Res, 2023, 16: 6023-6038.

[34] [34] Zhao ZH, Jiang BP, Zhang FY, et al. Association between the systemic immune-inflammation index and outcomes among atrial fibrillation patients with diabetes undergoing radiofrequency catheter ablation[J]. Clin Cardiol, 2023, 46(11): 1426-1433.

[35] [35] Kaplan E, Ekzler FA, Sariba H, et al. Effectiveness of the systemic immune inflammation index to predict atrial fibrillation recurrence after cryoablation[J]. Biomark Med, 2023, 17(2): 101-109.

[37] [37] Zhang X, Xiao XP, Ren XA, et al. Plasma miRNA-155 levels predict atrial fibrillation recurrence after cardioversion[J]. Heart Surg Forum, 2019, 22(2): E140-E148.

[38] [38] He WW, Tang R, Han JY, et al. The impact of MicroRNA-155 on the effect of cryoablation in paroxysmal atrial fibrillation[J]. Cell Mol Biol (Noisy-le-grand), 2023, 69(12): 144-149.

[39] [39] Liu SS, Guo HY, Zhu J, et al. Circulating circRNA expression profile and its potential role in late recurrence of paroxysmal atrial fibrillation post catheter ablation[J]. J Geriatr Cardiol, 2023, 20(11): 788-800.